HELIOS Kliniken

Hospital


Location: diverse, Germany (DE) DE

ISNI: 0000000105499953

ROR: https://ror.org/04fjkxc67

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC) (2019) Furlanetto J, Nekljudova V, Schneeweiss A, Thode C, Denkert C, Untch M, Bassy M, et al. Conference contribution Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials (2019) Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer JU, Seiler S, Denkert C, et al. Conference contribution Utility of the CPS plus EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy (2019) Marme F, Solbach C, Michel L, Fasching P, Schneeweiss A, Blohmer JU, Rezai M, et al. Conference contribution Does anti-acid treatment influence disease progression in SSc-ILD ? data from the German SSc-network (2019) Kreuter M, Bonella F, Blank N, Siegert E, Henes J, Worm M, Sunderkoetter C, et al. Conference contribution Long term outcomes of immunomodulatory drugs in SSc-ILD - data from the German SSc-network (2019) Kreuter M, Bonella F, Blank N, Siegert E, Henes J, Worm M, Sunderkoetter C, et al. Conference contribution Nab-paclitaxel improves disease-free survival in early breast cancer: GBG 69–Geparsepto (2019) Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, et al. Journal article Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis (2019) Robin M, De Wreede LC, Wolschke C, Schetelig J, Eikema DJ, Van Lint MT, Knelange NS, et al. Journal article Clinical relevance of collagen protein degradation markers C3M and C4M in the serum of breast cancer patients treated with neoadjuvant therapy in the geparquinto trial (2019) Banys-Paluchowski M, Loibl S, Witzel I, Mundhenke C, Lederer B, Solbach C, Karn T, et al. Journal article A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study (2019) Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, et al. Journal article Lipase Elevations and Diabetes under Checkpoint Inhibition - Experience in 80 Patients (2019) Weihkopf D, Satzger I, Zimmer L, Eigentler T, Haessel J, Heinzerling L, Herbst R, et al. Conference contribution